Crystal Arthritis

  • Ronald A. Asherson
  • Stephen H. Morgan
  • Graham R. V. Hughes

Abstract

The concept of joint disease being caused by crystal deposition in the synovial membrane is still relatively new, despite the legend that gout has become in medicine and history.

Keywords

Parathyroid Adenoma Crystal Deposition Serum Urate Gouty Arthritis Calcium Pyrophosphate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    O’Duffy J D. Clinical studies of acute pseudogout attacks. Arthritis Rheum 1976: 19 (SuppL 3) 349–352.PubMedCrossRefGoogle Scholar
  2. 2.
    Pritchard M H and Jessop J D Chondrocalcinosis in primary hyperparathyroidism Ann. Rheum. Dis 1977: 36 146–151.PubMedCrossRefGoogle Scholar
  3. 1.
    Lesch M and Nyhan W L A familial disorder of uric acid metabolism and central nervous system function Am. J. Med 1964: 36 561–570.PubMedCrossRefGoogle Scholar
  4. 2.
    Nyhan W L The Lesch-Nyhan syndrome In Vinken P J and Bruyn G W (eds.) Handbook of Clinical Neurology 1977: 29 263–278.Google Scholar
  5. 3.
    Kelley W N, Greene M L, Rosenbloom F M et al Hypoxanthine - guanine phosphoribosyl-transferase deficiency in gout Ann. Intern. Med 1969: 70 155–206.PubMedGoogle Scholar
  6. 4.
    Wilson J M, Young A B and Kelley W N Hypoxanthine-guanine phosphoribosyltransfer-ase deficiency N Engl. J. Med 1983: 309 900–910.PubMedCrossRefGoogle Scholar
  7. 1.
    MacFarlane D G and Dieppe P A Diuretic-induced gout in elderly women Br. J. Rheumatol 1985: 24 155–157.PubMedCrossRefGoogle Scholar
  8. 2.
    Gibson T Hyperuricaemic drugs In Scott J T (ed.) Copeman’s Textbook of the Rheumatic Diseases 6th Edn. 1986 (Churchill Livingstone) pp. 569–583.Google Scholar
  9. 3.
    Ellion B, Kovensky A, Hitchins G H, Metz E and Rondalls G R W. (1966). Metabolic studies on allopurinol, an inhibitor of xanthine oxidase. Biochem. Pharmacol 1966: 15 863–880.CrossRefGoogle Scholar
  10. 4.
    Webster E and Panush RS. Allopurinol hypersensitivity in a patient with severe, chronic, tophaceous gout. Arthritis Rheum 1985: 28 (6), 707–709.PubMedCrossRefGoogle Scholar
  11. 5.
    Young J L, Boswell R B and Nies A S. Severe allopurinol hypersensitivity, association with thiazides and prior renal compromise. Arch. Intern. Med 1974: 134 553–558.PubMedCrossRefGoogle Scholar
  12. 6.
    Meyrier A. Desensitization in a patient with chronic renal disease and severe allergy to allopurinol. Br. Med. J 1976: 2 458.PubMedCrossRefGoogle Scholar
  13. 7.
    Kelsey S M, Struthers G R and Blake B D R Desensitization to allopurinol Ann. Rheum. Dis 1987: 46 84 (letter).PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1988

Authors and Affiliations

  • Ronald A. Asherson
  • Stephen H. Morgan
  • Graham R. V. Hughes

There are no affiliations available

Personalised recommendations